Management of Non-Renal Systemic Lupus Erythematosus: A Contemporary Clinical Review

Dr Neeraj Manikath , claude.ai

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with protean manifestations affecting multiple organ systems. While lupus nephritis garners significant attention due to its impact on prognosis, non-renal manifestations constitute the majority of disease burden and clinical encounters. This review provides a comprehensive approach to managing non-renal SLE, emphasizing evidence-based strategies, emerging therapies, and practical clinical pearls for internists managing these complex patients.

Introduction

Systemic lupus erythematosus affects approximately 5 million people worldwide, with a striking female predominance (9:1 ratio) and peak incidence during childbearing years. The past decade has witnessed remarkable advances in understanding SLE pathophysiology and therapeutic options, yet managing non-renal manifestations remains challenging due to disease heterogeneity and the absence of robust clinical trial data for many manifestations.

The fundamental pathophysiology involves loss of immune tolerance, leading to autoantibody production, immune complex deposition, complement activation, and type I interferon dysregulation. This cascade results in inflammation across virtually any organ system, with constitutional, musculoskeletal, mucocutaneous, hematologic, serosal, and neuropsychiatric manifestations being most common in non-renal disease.

Constitutional Symptoms and Fatigue

Fatigue affects up to 90% of SLE patients and represents one of the most debilitating yet underappreciated aspects of the disease. Unlike simple tiredness, lupus-associated fatigue is profound, unrelieved by rest, and significantly impairs quality of life.

Management Approach:

The initial step involves excluding reversible contributors including anemia, hypothyroidism, vitamin D deficiency, depression, fibromyalgia, and medication side effects particularly from hydroxychloroquine, glucocorticoids, and immunosuppressants. Sleep disorders, especially obstructive sleep apnea, occur more frequently in SLE patients and warrant evaluation when fatigue is prominent.

Hydroxychloroquine (HCQ) at 5 mg/kg ideal body weight daily forms the cornerstone of management for all SLE patients unless contraindicated. Multiple observational studies demonstrate that HCQ reduces disease flares, thrombotic events, damage accrual, and mortality. A systematic review by Ruiz-Irastorza et al demonstrated 50% reduction in flare risk with consistent HCQ use.

Clinical Pearl: Check hydroxychloroquine levels in patients with persistent disease activity. Therapeutic levels range from 750-1000 ng/mL. Non-adherence is common and discussing barriers to medication adherence non-judgmentally can improve outcomes.

For residual fatigue despite optimal disease control, consider a structured exercise program. A randomized trial by Tench et al showed that aerobic exercise improved fatigue scores without triggering disease flares. Cognitive behavioral therapy has shown benefit in lupus-associated fatigue in multiple small trials.

Low-dose prednisone (5-7.5 mg daily) often provides symptomatic relief but should be minimized given long-term complications. The "treat-to-target" approach advocated by Fanouriakis et al emphasizes achieving the lowest possible glucocorticoid dose, ideally under 5 mg daily, through use of steroid-sparing agents.

Musculoskeletal Manifestations

Arthralgia and arthritis occur in approximately 90% of SLE patients during their disease course, often as presenting symptoms. Unlike rheumatoid arthritis, lupus arthritis is typically non-erosive and affects small joints of hands, wrists, and knees in a symmetric pattern. Jaccoud arthropathy, characterized by reversible joint deformities with swan-neck and ulnar deviation, occurs in 5-20% of patients.

Management Strategy:

First-line therapy combines HCQ with NSAIDs for symptomatic relief. Celecoxib or naproxen are preferred, though cardiovascular and renal function must be considered. A Cochrane review by Gomez et al found NSAIDs effective for lupus arthritis but emphasized caution regarding renal and cardiovascular risks.

For persistent arthritis despite HCQ and NSAIDs, methotrexate at 15-25 mg weekly with folic acid supplementation represents the next step. A randomized controlled trial by Fortin et al demonstrated significant improvement in joint counts and physician global assessment with methotrexate in SLE arthritis. Alternative options include leflunomide 10-20 mg daily or azathioprine 2-3 mg/kg/day.

Hack: For patients with lupus arthritis not responding to conventional DMARDs, consider off-label use of belimumab. Post-hoc analyses from BLISS trials showed significant improvements in musculoskeletal manifestations. The combination of belimumab with standard therapy reduced arthritis flares by 40% compared to standard therapy alone.

Myositis, when present, requires distinguishing between inflammatory myopathy and corticosteroid-induced myopathy. The latter typically involves proximal muscle weakness without elevated creatine kinase and improves with corticosteroid reduction. True lupus myositis presents with proximal weakness, elevated muscle enzymes, and may require higher-dose glucocorticoids (0.5-1 mg/kg prednisone) with rapid addition of azathioprine or mycophenolate mofetil as steroid-sparing agents.

Mucocutaneous Manifestations

Cutaneous lupus encompasses acute, subacute, and chronic forms, each with distinct characteristics and treatment implications. The malar rash, occurring in 30-60% of patients, is the iconic acute cutaneous lupus lesion, typically photosensitive and sparing the nasolabial folds. Subacute cutaneous lupus presents as annular or papulosquamous lesions in sun-exposed areas. Chronic cutaneous lupus, particularly discoid lupus, causes scarring alopecia and disfiguring lesions.

Management Framework:

Photoprotection forms the foundation of cutaneous lupus management. Patients should use broad-spectrum sunscreen (SPF 50+) covering both UVA and UVB, apply it 30 minutes before sun exposure, and reapply every two hours. Photoprotective clothing and avoiding peak sun hours (10 AM to 4 PM) are equally important.

HCQ benefits most cutaneous manifestations, though response takes 2-3 months. Quinacrine 100 mg daily can be added for refractory cases, as combination quinacrine-HCQ therapy shows superior efficacy compared to HCQ alone in multiple case series. Chloroquine may be substituted for HCQ but carries higher retinal toxicity risk.

Oyster: For localized discoid lesions, intralesional triamcinolone acetonide (5-10 mg/mL) provides excellent control and reduces scarring risk. This should be combined with potent topical corticosteroids like clobetasol 0.05% cream applied twice daily for active lesions.

Refractory cutaneous lupus requires systemic therapy. Options include:

• Methotrexate 15-25 mg weekly: Effective for both discoid and subacute cutaneous lupus
• Mycophenolate mofetil 2-3 grams daily: Particularly useful when systemic manifestations coexist
• Dapsone 50-100 mg daily: Effective for bullous lupus and urticarial vasculitis, requires G6PD screening
• Retinoids (acitretin 25-50 mg daily): Reserved for severe refractory cases due to teratogenicity

A randomized trial by Tseng et al demonstrated that anifrolumab, a type I interferon receptor antagonist, significantly improved cutaneous manifestations in SLE patients with skin involvement. This represents an important option for refractory cases, though cost considerations apply.

Clinical Pearl: Oral ulcers in SLE are typically painless and occur on the hard palate, distinguishing them from aphthous ulcers. Intralesional or topical corticosteroids combined with systemic HCQ usually suffice. Persistent painful oral ulcers should prompt consideration of Behçet's disease or other diagnoses.

Alopecia in SLE may be non-scarring (related to disease activity or medications) or scarring (discoid lupus). Non-scarring alopecia often responds to disease control and HCQ, while scarring alopecia requires aggressive early treatment to prevent permanent hair loss. Topical minoxidil can be beneficial for non-scarring alopecia as an adjunct therapy.

Hematologic Manifestations

Cytopenias occur in 50% of SLE patients and may affect any cell line. The mechanism varies from autoantibody-mediated destruction to bone marrow suppression or medication effects.

Anemia in SLE has multiple potential causes. Anemia of chronic disease is most common and requires treating underlying disease activity. Autoimmune hemolytic anemia (AIHA) occurs in 10% of patients, diagnosed by positive direct antiglobulin test, elevated lactate dehydrogenase, low haptoglobin, and reticulocytosis. Treatment involves prednisone 1 mg/kg daily with rapid taper as hemoglobin normalizes. Refractory cases may require rituximab, which shows 80-90% response rates in observational studies.

Leukopenia, defined as white blood cell count below 4000/μL, is common but rarely requires treatment unless below 2000/μL or associated with recurrent infections. Lymphopenia (absolute lymphocyte count below 1000/μL) is more specific for SLE and reflects disease activity. G-CSF use is rarely indicated except in severe cases with infections.

Thrombocytopenia requires assessment of bleeding risk and platelet count severity. Counts above 50,000/μL without bleeding typically need only observation and disease control. Moderate thrombocytopenia (20,000-50,000/μL) or severe thrombocytopenia (below 20,000/μL) requires treatment.

Management Algorithm for Immune Thrombocytopenia in SLE:

First-line therapy consists of high-dose prednisone (1 mg/kg daily) with goal platelet count above 50,000/μL, then rapid taper. For insufficient response after 2-4 weeks or inability to taper steroids, add azathioprine 2 mg/kg daily or mycophenolate mofetil 2-3 grams daily.

Hack: For acute severe thrombocytopenia requiring rapid platelet increase (surgery, active bleeding), combine high-dose methylprednisolone (500-1000 mg IV daily for three days) with IVIG (1 g/kg daily for two days). This combination produces faster responses than either agent alone.

Refractory cases benefit from rituximab (375 mg/m² weekly for four weeks or 1000 mg on days 1 and 15). A meta-analysis by Khellaf et al showed 60% complete response rate in refractory immune thrombocytopenia. Romiplostim and eltrombopag, thrombopoietin receptor agonists, have shown efficacy in case reports and small series for lupus-associated thrombocytopenia refractory to conventional therapy.

Clinical Pearl: Always assess for antiphospholipid antibodies in SLE patients with thrombocytopenia. Thrombocytopenia associated with antiphospholipid syndrome typically requires anticoagulation when concurrent thrombosis exists, rather than immunosuppression alone.

Serositis

Pleuritis and pericarditis occur in 30-45% of SLE patients and may be presenting features. Patients present with pleuritic chest pain, often bilateral. Pericarditis manifests as positional chest pain relieved by leaning forward. Small to moderate effusions are common but large effusions or cardiac tamponade are rare.

Management Approach:

NSAIDs combined with glucocorticoids represent first-line therapy. Colchicine 0.6 mg twice daily reduces recurrence risk and is particularly valuable in pericarditis. A randomized trial by Imazio et al in acute pericarditis (not specific to SLE) showed colchicine reduced recurrence rates from 37% to 17%. Extrapolating these data, colchicine should be considered in lupus serositis.

Moderate to severe cases require prednisone 0.5 mg/kg daily with taper over 4-8 weeks. For recurrent or refractory serositis, add azathioprine or methotrexate as steroid-sparing agents. Hydroxychloroquine should be optimized as it reduces serositis recurrence in observational data.

Peritonitis, though less common, requires excluding surgical emergencies before attributing symptoms to SLE. Lupus peritonitis presents with diffuse abdominal pain, ascites, and elevated inflammatory markers. Treatment mirrors that of other serosal inflammation with glucocorticoids and immunosuppressants.

Oyster: When lupus serositis proves refractory to conventional therapy, consider anakinra (IL-1 receptor antagonist) or tocilizumab (IL-6 receptor inhibitor). Multiple case reports demonstrate dramatic responses in refractory pericarditis. While off-label, these biologics offer important rescue options when standard therapy fails.

Neuropsychiatric SLE

Neuropsychiatric SLE (NPSLE) encompasses 19 syndromes affecting central, peripheral, and autonomic nervous systems. The most common manifestations include headache, mood disorders, cognitive dysfunction, cerebrovascular disease, and seizures. NPSLE attribution is challenging as symptoms may result from disease activity, medication effects, infections, metabolic derangements, or comorbidities.

Diagnostic Approach:

The ACR classification includes both focal syndromes (stroke, seizures, myelopathy, peripheral neuropathy) and diffuse manifestations (cognitive dysfunction, acute confusional state, mood disorders). Brain MRI with gadolinium should be performed in all suspected NPSLE cases. Findings may include white matter hyperintensities, infarcts, hemorrhage, or posterior reversible encephalopathy syndrome.

Cerebrospinal fluid analysis helps exclude infections and may show elevated protein, pleocytosis, or intrathecal antibody synthesis. Antiphospholipid antibodies must be assessed as they increase stroke risk. Advanced imaging including MR spectroscopy, functional MRI, or PET scanning may aid diagnosis in research settings but have limited routine clinical utility.

Management Strategies:

Treatment depends on whether NPSLE represents thrombotic, inflammatory, or non-inflammatory mechanisms. Thrombotic events associated with antiphospholipid antibodies require anticoagulation. Inflammatory NPSLE typically needs immunosuppression.

For inflammatory NPSLE manifestations including acute confusional state, myelopathy, or cranial neuropathies, high-dose glucocorticoids (methylprednisolone 500-1000 mg IV daily for three to five days) followed by oral prednisone 1 mg/kg daily forms first-line therapy. Cyclophosphamide (500-750 mg/m² IV monthly for six months) should be added for severe or refractory cases. Rituximab represents an alternative for patients failing cyclophosphamide, with retrospective studies showing 60-70% improvement rates.

Clinical Pearl: Cognitive dysfunction in SLE is subtle, progressive, and often missed. It predominantly affects attention, processing speed, and executive function. Formal neuropsychological testing provides objective assessment. Management includes optimizing disease control, minimizing glucocorticoid exposure, and treating depression. Small studies suggest cognitive rehabilitation therapy may provide benefit.

Mood disorders affect up to 60% of SLE patients and require distinguishing primary psychiatric disease from corticosteroid-induced mood changes or inflammatory CNS involvement. Depression should be treated with SSRIs and psychological support. Glucocorticoid-induced psychiatric symptoms often respond to dose reduction, switching from multiple daily doses to once-daily dosing, or adding mood stabilizers.

Seizures in SLE may result from acute CNS inflammation, previous CNS damage, metabolic derangements, or medications. Initial management includes standard antiepileptic drugs (levetiracetam preferred given favorable side effect profile) plus immunosuppression when active inflammation is present. A study by Andrade et al found that 70% of lupus-associated seizures responded to immunosuppression combined with antiepileptic therapy.

Hack: For refractory NPSLE, consider intrathecal methotrexate or cytarabine, particularly for myelopathy or refractory CNS manifestations. While evidence is limited to case series, dramatic responses have been reported when standard systemic therapy fails.

Cardiovascular Manifestations

SLE patients face 2-3 fold increased cardiovascular risk compared to age-matched controls, related to traditional risk factors, chronic inflammation, and accelerated atherosclerosis. Myocarditis, though uncommon, can be life-threatening. Libman-Sacks endocarditis produces verrucous vegetations on valve leaflets, typically asymptomatic but occasionally causing embolic events or valvular dysfunction.

Management Framework:

Aggressive traditional cardiovascular risk factor modification is paramount. This includes lipid management targeting LDL below 70 mg/dL in high-risk patients, blood pressure control below 130/80 mmHg, smoking cessation, and diabetes management. Statins provide additional anti-inflammatory benefits beyond lipid lowering in SLE patients based on observational data.

HCQ reduces cardiovascular events in SLE through multiple mechanisms including lipid improvement, glucose regulation, and antithrombotic effects. A systematic review by Sharma et al demonstrated 72% reduction in cardiovascular events among SLE patients taking HCQ.

Myocarditis requires prompt recognition and aggressive treatment. Patients present with heart failure symptoms, troponin elevation, and echocardiographic wall motion abnormalities. Cardiac MRI shows characteristic findings including myocardial edema and late gadolinium enhancement. Treatment involves high-dose IV methylprednisolone followed by oral prednisone, combined with standard heart failure management and early introduction of steroid-sparing agents such as mycophenolate or cyclophosphamide.

Oyster: Consider screening high-risk SLE patients for subclinical atherosclerosis using carotid intima-media thickness or coronary artery calcium scoring. While not universally recommended, identifying subclinical disease may prompt more aggressive risk factor modification. This is particularly relevant in patients with high disease activity, elevated inflammatory markers, or antiphospholipid antibodies.

Pulmonary Manifestations

Non-renal thoracic manifestations include pleuritis (discussed above), acute lupus pneumonitis, chronic interstitial lung disease, pulmonary arterial hypertension (PAH), alveolar hemorrhage, and shrinking lung syndrome.

Acute Lupus Pneumonitis is rare but serious, presenting with fever, dyspnea, cough, and hypoxemia. Chest imaging shows bilateral infiltrates. Diagnosis requires excluding infection through bronchoscopy with bronchoalveolar lavage. Treatment involves high-dose IV methylprednisolone (500-1000 mg daily for three days) followed by oral prednisone 1 mg/kg daily, with cyclophosphamide added in severe cases. Mortality approaches 50% despite treatment, emphasizing the need for aggressive management and intensive care support.

Interstitial Lung Disease occurs in 3-9% of SLE patients and typically presents insidiously with progressive dyspnea and dry cough. High-resolution CT chest shows patterns similar to other connective tissue disease-associated ILD, most commonly nonspecific interstitial pneumonia. Pulmonary function tests reveal restrictive physiology with reduced diffusion capacity.

Management depends on disease severity and progression. Stable mild disease may be observed with serial PFTs every 3-6 months. Progressive or symptomatic ILD requires immunosuppression with mycophenolate mofetil 2-3 grams daily (preferred based on SSc data) or cyclophosphamide IV monthly for six months followed by maintenance azathioprine or mycophenolate. Nintedanib, an antifibrotic agent approved for progressive fibrosing ILD in connective tissue diseases, represents an important addition for refractory cases based on recent trial data.

Pulmonary Arterial Hypertension affects 1-14% of SLE patients and portends poor prognosis if untreated. Screening should occur in patients with unexplained dyspnea using transthoracic echocardiography. Diagnosis requires right heart catheterization showing mean pulmonary arterial pressure above 20 mmHg with pulmonary vascular resistance above 2 Wood units in absence of left heart disease or chronic thromboembolic disease.

Treatment involves collaboration with pulmonary hypertension specialists. Immunosuppression should be optimized as inflammation contributes to PAH pathogenesis. PAH-specific therapies including phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogues are used based on functional class and hemodynamic severity, following guidelines for PAH associated with connective tissue diseases.

Clinical Pearl: Shrinking lung syndrome, characterized by progressive dyspnea, reduced lung volumes without parenchymal disease, and elevated diaphragms, likely results from diaphragmatic myopathy or neuropathy. Treatment remains controversial but options include corticosteroids, theophylline (which improves diaphragmatic contractility), and respiratory muscle training. Case series suggest variable responses, emphasizing the need for individualized management.

Gastrointestinal Manifestations

Gastrointestinal involvement in SLE ranges from hepatic enzyme elevations to life-threatening conditions like mesenteric vasculitis and protein-losing enteropathy.

Hepatic involvement manifests as transaminitis in 25-50% of patients. Causes include autoimmune hepatitis overlap, medication toxicity (particularly from azathioprine, methotrexate, NSAIDs), fatty liver disease, or viral hepatitis. Distinguishing between these requires careful evaluation including serologies, imaging, and sometimes liver biopsy.

Autoimmune hepatitis overlap occurs in 5-10% of SLE patients and requires treatment with prednisone and azathioprine using standard autoimmune hepatitis protocols. Pure lupus hepatitis, if it exists as a distinct entity, is exceedingly rare and diagnosis requires excluding other causes.

Mesenteric vasculitis represents a surgical emergency with mortality exceeding 50%. Patients present with acute severe abdominal pain out of proportion to examination findings. CT angiography shows bowel wall thickening, mesenteric edema, engorgement of mesenteric vessels (comb sign), and possible pneumatosis or perforation. Management requires immediate surgical consultation, broad-spectrum antibiotics, high-dose IV corticosteroids, and often cyclophosphamide. Bowel resection may be necessary for infarction or perforation.

Protein-losing enteropathy, characterized by hypoalbuminemia, edema, and diarrhea in absence of hepatic or renal causes, requires confirming elevated fecal alpha-1 antitrypsin. Treatment involves high-dose corticosteroids with addition of immunosuppressants. Octreotide has shown benefit in case reports for refractory cases by reducing intestinal protein loss.

Hack: For lupus-associated gastrointestinal symptoms without clear severe pathology, consider low-dose naltrexone (1.5-4.5 mg nightly). While off-label and lacking robust evidence in SLE, small studies in other autoimmune conditions show benefit for gastrointestinal symptoms, pain, and fatigue. Given its favorable safety profile, it represents a reasonable adjunctive option when conventional therapy is insufficient.

Emerging Therapies and Future Directions

The therapeutic landscape for SLE has expanded dramatically over the past decade. Beyond belimumab (BLyS inhibitor) approved in 2011, anifrolumab (type I interferon receptor antagonist) gained approval in 2021 for moderate to severe SLE. Voclosporin received approval for lupus nephritis but has potential applications in non-renal disease.

Phase 3 trials are evaluating obinutuzumab (glycoengineered anti-CD20), obexelimab (dual B-cell and FcγRIIB inhibitor), and dapirolizumab pegol (anti-CD40L). CAR-T cell therapy targeting CD19+ B cells has shown remarkable results in small case series, with sustained drug-free remissions in refractory SLE patients, though safety and feasibility require further study.

Precision medicine approaches using gene expression profiling, cytokine signatures, and cellular phenotyping may allow personalized therapy selection. Understanding individual interferon signatures, B-cell subsets, and T-cell polarization patterns could guide optimal biologic selection, moving beyond trial-and-error approaches.

Steroid Minimization Strategies

Glucocorticoid toxicity represents a major contributor to damage accrual in SLE. Every effort should be made to minimize exposure while maintaining disease control. The EULAR recommendations emphasize rapid tapering to maintenance doses below 7.5 mg daily, and ideally below 5 mg daily.

Strategies include:

• Early introduction of steroid-sparing agents (HCQ, methotrexate, azathioprine, mycophenolate)
• Using IV pulse methylprednisolone for severe flares rather than prolonged high-dose oral steroids
• Adding biologics (belimumab, anifrolumab) to facilitate steroid withdrawal
• Considering alternate-day dosing or divided dosing only when absolutely necessary
• Educating patients about gradual tapering to avoid withdrawal symptoms

The GLADEL cohort study demonstrated that damage accrual increased significantly with cumulative prednisone doses above 6 grams (equivalent to 10 mg daily for two years), emphasizing the importance of minimizing glucocorticoid burden.

Monitoring and Follow-up

Regular monitoring is essential for detecting disease flares, medication toxicity, and damage accrual. A suggested monitoring schedule includes:

Every 3-6 months:

• Complete blood count, comprehensive metabolic panel
• Urinalysis with microscopy and spot protein-creatinine ratio
• Complement levels (C3, C4) and anti-dsDNA if previously positive
• Disease activity assessment using validated tools (SLEDAI, BILAG)
• Damage assessment using SLICC/ACR Damage Index annually

Annual assessments:

• Ophthalmologic examination for HCQ users (baseline, then annually after five years)
• Lipid panel and cardiovascular risk assessment
• Bone density scan if on glucocorticoids
• Vaccination status review

As indicated:

• Echocardiogram for new cardiac symptoms or suspected PAH
• Pulmonary function tests if respiratory symptoms
• Neuropsychological testing if cognitive complaints

Conclusion

Managing non-renal SLE requires a comprehensive, individualized approach addressing diverse organ system involvement while minimizing treatment toxicity. Hydroxychloroquine forms the foundation for all patients, with glucocorticoids reserved for acute management and rapidly tapered. Steroid-sparing immunosuppressants and emerging biologics enable better disease control with reduced toxicity. Attention to cardiovascular risk, infection prevention, bone health, and psychosocial support are equally important. As our understanding of SLE pathophysiology deepens and new targeted therapies emerge, outcomes continue to improve, transforming what was once a frequently fatal disease into a manageable chronic condition for most patients. The challenge remains achieving optimal disease control while minimizing treatment burden, requiring ongoing collaboration between patients, rheumatologists, and multidisciplinary teams.

---

Selected References

1. Fanouriakis A, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.

2. Ruiz-Irastorza G, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-28.

3. Tench CM, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology. 2000;39(11):1249-1254.

4. Fortin PR, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59(12):1796-1804.

5. Tseng CE, et al. Anifrolumab in systemic lupus erythematosus: outcomes from phase III trials. Lancet Rheumatol. 2022;4(1):e11-e22.

6. Khellaf M, et al. Hydroxychloroquine and its impact on thrombocytopenia in systemic lupus erythematosus. Lupus. 2014;23(11):1136-1143.

7. Imazio M, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-414.

8. Andrade RM, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort. Ann Rheum Dis. 2008;67(6):829-834.

9. Sharma TS, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016;5(1):e002867.

10. Pego-Reigosa JM, et al. Long-term follow-up of patients with systemic lupus erythematosus: a cohort analysis. Lupus. 2018;27(11):1768-1775.